C12N 2740/14034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/14034 (Use of virus or viral component as vaccine) appears on 21 US grants and 26 published applications in this corpus.
Search patents in C12N- Granted patents
- 21
- Published applications
- 26
- Assignees
- 31
- Inventors
- 68
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 2 |
| 2018 | 2 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 3 |
| 2021 | 2 | 1 |
| 2022 | 2 | 3 |
| 2023 | 1 | 4 |
| 2024 | 1 | 2 |
| 2025 | 1 | 5 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus20 May 2025US 12,303,560 B2Medigen, Inc.
- Alphavirus neoantigen vectors8 Oct 2024US 12,109,257 B2Gritstone Bio, Inc.
- Recombinant bovine immunodeficiency virus gag virus-like particles containing influenza immunogens14 Feb 2023US 11,576,965 B2Medigen, Inc.
- Alphavirus antigen vectors29 Nov 2022US 11,510,973 B2Gritstone Bio, Inc.
- Htlv-1 nucleic acid lipid particle vaccine18 Dec 2025US 2025/0381264 A2Daiichi Sankyo Company, Limited
- Replicant / stav for disease treatment and methods of use30 Oct 2025US 2025/0332233 A1
- Non-replicating bovine infectious lymphoma virus (blv) and cells for producing same21 Aug 2025US 2025/0263740 A1The University of Tokyo
- Alphavirus antigen vectors7 Aug 2025US 2025/0249084 A1Gritstone Bio, Inc.
- Immune checkpoint inhibitor co-expression vectors23 Jan 2025US 2025/0025544 A1Gritstone Bio, Inc.
Most cited
By later US patents
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Inactivating enveloped viruses with a merocyanine dye40US 4,775,625 AThe Medical College of Wisconsin, Inc. · 1988
- Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV11US 4,701,416 ACetus Corporation · 1987
- HIV-1 vectors7US 5,837,512 AUniversity of Medicine & Dentistry of NJ · 1998
- Compositions and methods for delivery of genetic material6US 6,197,755 B1Apollan, Inc. · 2001